News and Updates

Phanes Therapeutics expands its clinical trial with Merck to test Spevatamig alongside KEYTRUDA and chemotherapy for treating biliary tract cancer.

Pharmability gains Swedish MPA approval for a Phase Ib trial of TIR-C, a promising new therapeutic candidate for treating chronic atopic dermatitis.

Mabwell’s bulumtatug fuvedotin shows clinical potential for triple-negative breast cancer patients previously treated with topoisomerase I inhibitors.

New 2-year data confirms 4D-150 gene therapy provides sustained vision improvements for wet AMD patients, potentially reducing the need for recurring injections.

OMEICOS has initiated a Phase 3 trial for OMT-28, a potential breakthrough treatment targeting mitochondrial disease. Learn about this new clinical milestone.

CMS is tightening oversight on RPM vendors. Learn how these regulatory shifts impact data integrity and compliance for clinical trial sponsors.

Explore how the innovative combination of Glofitamab and Englumafusp Alfa is revolutionizing cancer therapy in recent Phase 1 clinical trial findings.

The FDA has granted Priority Review to Dyne Therapeutics' z-rostudirsen. Learn how this novel therapy aims to treat Duchenne Muscular Dystrophy.

The FDA has authorized a new gene therapy trial for Tay-Sachs and Sandhoff diseases. Discover how this breakthrough could redefine treatment for rare disorders.

New trial data shows oral avatrombopag effectively reduces chemotherapy delays by managing platelet counts, offering a breakthrough for cancer care.